Timothy S. Nelson


Tim served as MAP Pharmaceuticals’ President and Chief Executive Officer and as a Member of its Board of Directors from April 2005 until March 2013 when the company was acquired by Allergan for $960 million. Tim also serves on the board of directors of Dermavant, a private biopharmaceutical company, since April 2019.

From 1998 to 2005, Tim served as Senior Vice President of Commercial and Business Development at DURECT Corporation. From 1992 to 1998, Tim held various senior management positions with Medtronic, including Business Director of the Neurological Division for Europe, the Middle East and Africa from 1996 to 1998, and Manager of Drug Delivery Ventures from 1992-1996.

Tim has served on other Boards of Directors, including as Chairman of the Board of Civitas, a private biopharmaceutical company focused on treating undermet medical needs in neurological indications, from December 2013 to October 2014, when the company was acquired by Acorda Therapeutics for $525 million. Tim also served on the Board of Directors of Surmodics, a public medical technology company, from February 2014 to March 2015.

Tim earned a Bachelor of Chemical Engineering from the University of Minnesota and a Master of Management with distinction from the J.L. Kellogg Graduate School of Management at Northwestern University.